MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015)
Conditions: Arteriosclerosis; Hypercholesterolaemia Interventions: Drug: MK-0616; Drug: Placebo Sponsor: Merck Sharp & Dohme LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials